Literature DB >> 25187198

Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs' administrative database study.

Zaki Abou Zahr1, Andrew Spiegelman, Maria Cantu, Bernard Ng.   

Abstract

The aim of this study was to validate a novel technique that predicts stopping of disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) from the Veterans Affairs (VA) database and compare infection risks of rheumatoid arthritis patients who stopped versus continued DMARDs/BA perioperatively. We identified 6,024 patients on 1 DMARD or BA in the perioperative period between 1999 and 2009. Time gap between medication stop date and the next start date predicted drug stoppage (X). Time gap between surgery date and stop date predicted whether stoppage was before surgery (Y). Chart review from Houston VA was used for validation. ROC analyses were performed on chart review data to obtain X and Y cutoffs. The primary endpoints were wound infections and other infections within 30 days. ROC analyses found X ≥ 33 (AUC = 0.954) and Y ≥ -11 (AUC = 0.846). Risk of postoperative infections was not different when stopping and continuing DMARDs/BA preoperatively. Stopping BA after surgery was associated with higher odds of postoperative wound (OR 14.15, 95 % CI 1.76-113.76) and general infection (OR 9.2, 95 % CI 1.99-42.60) compared to not stopping. Stopping DMARDs after surgery was associated with increased risk of postoperative general infection (OR 1.84, 95 % CI 1.07-3.16) compared with not stopping. There was positive association between stopping DMARDs after surgery and postoperative wound infection but failed to achieve statistical significance (OR 1.67, 95 % CI 0.96-2.91). There was no significant difference in postoperative infection risk when stopping or continuing DMARD/BA. Our new validated method can be utilized in the VA and other databases to predict drug stoppage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187198     DOI: 10.1007/s00296-014-3121-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

Review 1.  Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis.

Authors:  Marie Hudson; Samy Suissa
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis.

Authors:  Helga Radner; Josef S Smolen; Daniel Aletaha
Journal:  Rheumatology (Oxford)       Date:  2010-10-29       Impact factor: 7.580

3.  The influence of cortisol on wound healing of the skin and distant connective tissue response.

Authors:  H Oxlund; I Fogdestam; A Viidik
Journal:  Surg Gynecol Obstet       Date:  1979-06

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  US Department of Veterans Affairs medical care system as a resource to epidemiologists.

Authors:  E J Boyko; T D Koepsell; J M Gaziano; R D Horner; J R Feussner
Journal:  Am J Epidemiol       Date:  2000-02-01       Impact factor: 4.897

Review 6.  Steroids, retinoids, and wound healing.

Authors:  G M Anstead
Journal:  Adv Wound Care       Date:  1998-10       Impact factor: 4.730

7.  Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis.

Authors:  J Sany; J M Anaya; F Canovas; B Combe; C Jorgensen; S Saker; M N Thaury; J P Gavroy
Journal:  J Rheumatol       Date:  1993-07       Impact factor: 4.666

8.  Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.

Authors:  A Ruyssen-Witrand; L Gossec; C Salliot; M Luc; M Duclos; S Guignard; M Dougados
Journal:  Clin Exp Rheumatol       Date:  2007 May-Jun       Impact factor: 4.473

9.  Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate.

Authors:  R S Perhala; W S Wilke; J D Clough; A M Segal
Journal:  Arthritis Rheum       Date:  1991-02

Review 10.  Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review.

Authors:  Herwig Pieringer; Kathrin Danninger; Nikolay Tzaribachev; Nikolaus Böhler; Erich Pohanka; Manfred Herold
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

View more
  8 in total

1.  Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

Review 2.  Perioperative management of immunosuppression in patients with rheumatoid arthritis.

Authors:  Michael D George; Joshua F Baker
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 3.  Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression.

Authors:  Joshua F Baker; Michael D George
Journal:  Curr Rheumatol Rep       Date:  2019-03-08       Impact factor: 4.592

4.  Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.

Authors:  Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

Review 5.  Perioperative management of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society for Rheumatology.

Authors:  Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger
Journal:  Z Rheumatol       Date:  2022-03-02       Impact factor: 1.372

6.  [Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].

Authors:  Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger
Journal:  Z Rheumatol       Date:  2021-12-20       Impact factor: 1.372

7.  Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.

Authors:  Michael D George; Joshua F Baker; Kevin L Winthrop; Seth D Goldstein; E Alemao; Lang Chen; Qufei Wu; Fenglong Xie; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2020-03-24       Impact factor: 19.103

8.  Validation of discharge diagnosis codes to identify serious infections among middle age and older adults.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; William Schaffner; Robert A Greevy; Edward F Mitchel; Carlos G Grijalva
Journal:  BMJ Open       Date:  2018-06-19       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.